February 13, 2018 09:13 AM ESTUpdated 09:26 AM

$100B in NIH-funded research played an important role in all 210 new drugs approved over 7 years — study

John Carroll

Editor & Founder

The next time someone challenges the importance of NIH-funded research in drug development, you might want to point them to a new study that highlights …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

$100B in NIH-funded research played an important role in all 210 new drugs approved over 7 years — study

John Carroll

Editor & Founder

Sign up to read this article for free.

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Athira gives up on lead Alzheimer’s drug, switches tack to ALS

Charles River to close ‘15 smaller sites’ as demand for early research declines

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Nkarta drops another cancer program as it leans into autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

$100B in NIH-fund­ed re­search played an im­por­tant role in all 210 new drugs ap­proved over 7 years — study

John Carroll

Editor & Founder

Sign up to read this article for free.

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Athi­ra gives up on lead Alzheimer’s drug, switch­es tack to ALS

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

$100B in NIH-funded research played an important role in all 210 new drugs approved over 7 years — study

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Athira gives up on lead Alzheimer’s drug, switches tack to ALS

Charles River to close ‘15 smaller sites’ as demand for early research declines

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Nkarta drops another cancer program as it leans into autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks